Editorial

• Volume 2 Number 2 April-June 2009

Conference reports

• 16th Conference on Retroviruses and Opportunistic Infections (CROI), 8-11 February 2009, Montreal

• HIV infection in the brain: a long-term limitation of HAART?

• When to start HAART – a key research question with the least available data

• NA ACCORD results support the importance of the START study: response to researchers

• Higher rates of non-AIDS cancers in HIV-positive people

• Assessing the cardiovascular impact of HIV, abacavir, and new signals for lopinavir/r

• HDL particle concentration predicts cardiovascular disease in SMART

• No effect of hormonal contraception on HIV disease progression in large multi-country cohort

• Pregnancy, family planning, and HIV acquisition in HPTN 039

• Progression and regression of pre-malignant cervical lesions in HIV-positive women from Soweto

• CD4 count >250 not predictive of rash-associated hepatoxicity among women initiating nevirapine-based ART in Zambia, Thailand, and Kenya

• Pharmacokinetic studies in very young infants

• Double-dose lopinavir/ritonavir provides insufficient lopinavir exposure in children receiving rifampicin

• PI-based ART in HIV-infected and HIV/TB coinfected children in South Africa

• Children on HAART do extremely well at South African clinic

• Etravirine dose selection in children aged 6 to 17

• Preliminary results from first paediatric raltegravir study

• New boosting alternatives to ritonavir: GS-99350 and SPI-452

• Nevirapine: fluconazole and TB treatment

• Effect of single dose nevirapine on subsequent nevirapine-containing HAART: long term outcomes

• HIV and TB from CROI

• 4th South African AIDS Conference, 31 March-3 April 2009, Durban, South Africa

• HAART coverage and unmet need in South Africa

• HIV-related medical interventions needed in Southern Africa

• 10th Internationall Workshop on Clinical Pharmacology of HIV Therapy, 15-17 April 2009, Amsterdam

• Genetic markers linked to early discontinuation of three antiretrovirals

• How much (or how little) ritonavir do you need to boost another PI?

Treatment access

• FDA approval of generic ARVs

• HIV medicine prices in the South African private sector

TB coinfection

• TMC207 reduces time to sputum conversion in phase II trial in patients with drug-resistant TB

• Relationship between TB IRIS and drug-resistant TB

• High risk of stavudine substitution associated with TB treatment

• WHO global TB control report highlights that 25% of TB-related deaths occur in HIV-positive people

Other news

• Review of the HSRC’s prevalence, incidence, behaviour and communication survey

• Nations should reject UN drug policy

• Job vacancy: editor post for the Southern African HIV Nursing Magazine

On the web

• Online videos from Community Media Trust

• Human rights documentation and advocacy: a guide for organisations of people who use drugs

PDFs

• Volume 2 Number 2 April-June 2009 PDF